Kezdőlap・Részvénylista・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Nyitva

SzektorEgészségügy

258.57 9.46

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

231.82

Maximum

263.86

Fő mutatók
By Trading Economics
Bevétel	262M -15M
Értékesítés	1.6M 996M
Egy részvényre jutó nyereség	2.06
Profit margin	-1.486
Munkavállalók	18,300
EBITDA	-135M 64M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	-1.67% downside

Osztalékok
By Acuity
Következő eredményjelentés	2026. aug. 5.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	2.8B 11B
Előző nyitás	249.11
Előző zárás	258.57

Hangulat hírek alapján

By Acuity

10%

90%

14 / 340 Rangsor szerint Healthcare

Charles River Laboratories International Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 4. 19:16 UTC

Correlated Moves

Charles River Laboratories is rising amid positive momentum in the small-cap market, supported by a drop in crude oil prices that eases inflation concerns.

2026. aug. 3. 22:06 UTC

Charles River Laboratories shares are slightly higher in after-hours trading, supported by stronger-than-expected manufacturing data showing a rise in the PMI for July.

2026. júl. 31. 19:46 UTC

Correlated Moves

Charles River Laboratories reported first-quarter revenue of $1.02 billion and adjusted EPS of $2.06, but shares are lower amid broader market declines.

2026. júl. 30. 23:01 UTC

Shares of Charles River Laboratories are higher in after-market trading, reaching a peak above Thursday's close and remaining strong relative to recent trends.

2026. júl. 29. 19:18 UTC

Correlated Moves

Charles River Laboratories is lower today amid broader market declines and investor caution ahead of the Federal Reserve's monetary policy announcement.

2026. júl. 28. 18:02 UTC

Charles River Laboratories is trading higher today, continuing a strong rally since Monday. The stock remains above its 20-day moving average.

2026. júl. 27. 17:36 UTC

News

Correlated Moves

Charles River Laboratories is trading lower today, reflecting a decline since Friday. The company announced a collaboration with Arovella Therapeutics for GMP sequencing services.

2026. júl. 23. 00:01 UTC

Charles River Laboratories is higher in after-hours trading, maintaining a cumulative gain since Wednesday amid no specific news to explain the movement.

2026. júl. 22. 22:01 UTC

Charles River Laboratories shares are higher in after-hours trading, reflecting a notable increase since Wednesday's close and positioning above the 20-day moving average.

2026. júl. 21. 21:01 UTC

Charles River Laboratories shares moved lower in after-market trading, continuing a steady decline since Tuesday's close amid broader market concerns.

2026. júl. 20. 21:01 UTC

Shares of Charles River Laboratories International Inc are lower in after-market trading, continuing a trend of declines with no specific news to explain the movement.

Társak összehasonlítása

Árváltozás

Charles River Laboratories International Inc Előrejelzés

Célár

By TipRanks

-1.67% elmozdulás lefelé

12 hónapos előrejelzés

Átlag 230.2 USD -1.67%

Magas 265 USD

Alacsony 213 USD

12 Wall Street elemző 12 hónapos célárain alapulva a(z)Charles River Laboratories International Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

12 ratings

Vétel

Tartás

Eladás

12 Wall Street elemző célárain alapulva a(z)Charles River Laboratories International Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

14 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.